Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Robert T, Bailer"'
Autor:
Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-11 (2024)
Abstract Ebola virus disease (EVD) is a filoviral infection caused by virus species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV). We investigated the safety and immunogenicity of a heterologous prime-boost reg
Externí odkaz:
https://doaj.org/article/a738fdd17f884be498b68c55cc2e29cd
Autor:
Yen-Ting Lai, Tao Wang, Sijy O’Dell, Mark K. Louder, Arne Schön, Crystal S. F. Cheung, Gwo-Yu Chuang, Aliaksandr Druz, Bob Lin, Krisha McKee, Dongjun Peng, Yongping Yang, Baoshan Zhang, Alon Herschhorn, Joseph Sodroski, Robert T. Bailer, Nicole A. Doria-Rose, John R. Mascola, David R. Langley, Peter D. Kwong
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
Temsavir, a compound that inhibits HIV entry by binding envelope (Env), is currently in clinical development. Here, Lai et al. identify a more than 10-fold improved compound and, using lattice engineering, obtain crystal structures that give insights
Externí odkaz:
https://doaj.org/article/8c1780f80cef41df909afde553e1a2ab
Autor:
James J. Steinhardt, Javier Guenaga, Hannah L. Turner, Krisha McKee, Mark K. Louder, Sijy O’Dell, Chi-I Chiang, Lin Lei, Andrey Galkin, Alexander K. Andrianov, Nicole A. Doria-Rose, Robert T. Bailer, Andrew B. Ward, John R. Mascola, Yuxing Li
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Broadly neutralizing antibodies targeting HIV Env could potentially be utilized as therapeutics. Here, Steinhardt et al. engineer a trispecific antibody with specificity for the receptor-binding site, a conserved Env glycan patch and the Env membrane
Externí odkaz:
https://doaj.org/article/03eaed1d2e664ef483d4e8852e3946e7
Autor:
Young D. Kwon, Gwo-Yu Chuang, Baoshan Zhang, Robert T. Bailer, Nicole A. Doria-Rose, Tatyana S. Gindin, Bob Lin, Mark K. Louder, Krisha McKee, Sijy O’Dell, Amarendra Pegu, Stephen D. Schmidt, Mangaiarkarasi Asokan, Xuejun Chen, Misook Choe, Ivelin S. Georgiev, Vivian Jin, Marie Pancera, Reda Rawi, Keyun Wang, Rajoshi Chaudhuri, Lisa A. Kueltzo, Slobodanka D. Manceva, John-Paul Todd, Diana G. Scorpio, Mikyung Kim, Ellis L. Reinherz, Kshitij Wagh, Bette M. Korber, Mark Connors, Lawrence Shapiro, John R. Mascola, Peter D. Kwong
Publikováno v:
Cell Reports, Vol 22, Iss 7, Pp 1798-1809 (2018)
Summary: Highly effective HIV-1-neutralizing antibodies could have utility in the prevention or treatment of HIV-1 infection. To improve the potency of 10E8, an antibody capable of near pan-HIV-1 neutralization, we engineered 10E8-surface mutants and
Externí odkaz:
https://doaj.org/article/20803a2ba97341ed985e9c54c91c448e
Autor:
Adam D. DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Sarah Andrews, Adrian McDermott, Michelle C. Crank, Richard A Koup, Richard M. Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood
Publikováno v:
npj Vaccines, Vol 2, Iss 1, Pp 1-6 (2017)
Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed
Externí odkaz:
https://doaj.org/article/e2d2da024d7c4739ac5a7e10fb271246
Autor:
Cristina Carter, Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Grace L Chen, Shital M Patel, Patricia Winokur, Robert Belshe, Cornelia L Dekker, Barney S Graham, Julie E Ledgerwood, VRC 703 study team
Publikováno v:
PLoS ONE, Vol 14, Iss 9, p e0222178 (2019)
BackgroundSeasonal influenza results in significant morbidity and mortality worldwide, but the currently licensed inactivated vaccines generally have low vaccine efficacies and could be improved. In this phase 1 clinical trial, we compared seasonal i
Externí odkaz:
https://doaj.org/article/773f84c8b2754fefbbb0e4d8279bce2c
Autor:
Martin R Gaudinski, Emily E Coates, Katherine V Houser, Grace L Chen, Galina Yamshchikov, Jamie G Saunders, LaSonji A Holman, Ingelise Gordon, Sarah Plummer, Cynthia S Hendel, Michelle Conan-Cibotti, Margarita Gomez Lorenzo, Sandra Sitar, Kevin Carlton, Carolyn Laurencot, Robert T Bailer, Sandeep Narpala, Adrian B McDermott, Aryan M Namboodiri, Janardan P Pandey, Richard M Schwartz, Zonghui Hu, Richard A Koup, Edmund Capparelli, Barney S Graham, John R Mascola, Julie E Ledgerwood, VRC 606 Study Team
Publikováno v:
PLoS Medicine, Vol 15, Iss 1, p e1002493 (2018)
BACKGROUND:VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being evaluated in a Phase IIb adult HIV-1 prevention efficacy trial. VRC01LS is a mo
Externí odkaz:
https://doaj.org/article/7064e5c4178543e0a29e54c0e8e750e5
Autor:
Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Myeisha Paskel, Kanta Subbarao, Edwin Anderson, David I Bernstein, Buddy Creech, Harry Keyserling, Paul Spearman, Peter F Wright, Barney S Graham, Julie E Ledgerwood, VRC 702 study team
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0206837 (2018)
BACKGROUND:Children are susceptible to severe influenza infections and facilitate community transmission. One potential strategy to improve vaccine immunogenicity in children against seasonal influenza involves a trivalent hemagglutinin DNA prime-tri
Externí odkaz:
https://doaj.org/article/67936566033b4b438ee217c20baa6439
Autor:
Kenneth H Mayer, Kelly E Seaton, Yunda Huang, Nicole Grunenberg, Abby Isaacs, Mary Allen, Julie E Ledgerwood, Ian Frank, Magdalena E Sobieszczyk, Lindsey R Baden, Benigno Rodriguez, Hong Van Tieu, Georgia D Tomaras, Aaron Deal, Derrick Goodman, Robert T Bailer, Guido Ferrari, Ryan Jensen, John Hural, Barney S Graham, John R Mascola, Lawrence Corey, David C Montefiori, HVTN 104 Protocol Team, and the NIAID HIV Vaccine Trials Network
Publikováno v:
PLoS Medicine, Vol 14, Iss 11, p e1002435 (2017)
BACKGROUND:VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a broad range of HIV-1 primary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterally to
Externí odkaz:
https://doaj.org/article/b3def334b9d34d36925838d06d4bd961
Autor:
Peifeng Chen, Anita Arthur, Kaitlyn M. Morabito, Kristin Leach, Xiaolin Wang, Grace L. Chen, Attila Nagy, Lauren A. Chang, Jon Cooper, Amy L. Chamberlain, Janel Holland-Linn, Olga Vasilenko, Alicia T. Widge, Shufeng Bai, Judith A Stein, LaSonji A. Holman, Cristina Carter, Iris Pittman, Deepika Gollapudi, Lisa A. Kueltzo, Colleen Fridley, Michelle C. Crank, Amritha Menon, William Whalen, Mridul Ghosh, Cynthia S. Hendel, Martha Nason, Amy Liu, Althaf Hussain, Laura Novik, Pernell Williams, Maria Burgos Florez, Robert T. Bailer, Thuy Nguyen, Brenda Larkin, Tracy J. Ruckwardt, Pamela Costner, Lam Le, Zhong Zhao, Elizabeth Carey, Vera Ivleva, Jennifer Walters, John R. Mascola, Jennifer Cunningham, Olga Trofymenko, Ya-chen Chang, Somia P. Hickman, Martin R. Gaudinski, Richard M. Schwartz, Slobodanka D. Manceva, Kevin Carlton, Barney S. Graham, Rahul Ragunathan, Jason G. D. Gall, Ana M. Ortega-Villa, Colin Tran, Sarah H. Plummer, Abidemi Ola, Ro Shauna S Rothwell, Ingelise J. Gordon, Mingzhong Chen, Jamie G. Saunders, Aba Mensima Eshun, Bob C. Lin, Azad Kumar, Nina M. Berkowitz, Xun Liu, Cora Trelles Cartagena, Emily Phung, Galina Yamshchikov, Joe Horwitz, Sarah O’Connell, Florence Kaltovich, Floreliz Mendoza, LaShawn Requilman, Man Chen, Preeti Apte, Christopher Lee, Renunda Hicks
Publikováno v:
Lancet Respir Med
Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sust